HTA and Reimbursement Status of Metastatic Hormone‑Sensitive Prostate Cancer, Non-Metastatic Castration-Resistant Prostate Cancer, and Metastatic Castration-Resistant Prostate Cancer Treatments in Europe: A Patient Access Landscape Review

Background: Prostate cancer is the second most common cancer in men, with up to one-third of men being diagnosed in their lifetime. Recently, novel therapies have received regulatory approval with significant improvement in overall survival for metastatic castration-resistant prostate cancer, metast...

Descripción completa

Detalles Bibliográficos
Autores principales: Bencina, Goran, Petrova, Elina, Sönmez, Demet, Matos Pereira, Sonia, Dimitriadis, Ioannis, Salomonsson, Stina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Columbia Data Analytics, LLC 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10290826/
https://www.ncbi.nlm.nih.gov/pubmed/37366384
http://dx.doi.org/10.36469/001c.75208

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10290826/
https://www.ncbi.nlm.nih.gov/pubmed/37366384
http://dx.doi.org/10.36469/001c.75208

Ejemplares similares